This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential.
I participated in 2004 in the creation of the Bioméditerranée cluster foreshadowing the Eurobiomed competitiveness cluster, which is currently the catalyst of the health sector in the Provence-Alpes-Côte d’Azur and Languedoc-Roussillon regions with 400 companies, 8 Universities, 400 research centres, 4 University Hospitals Centres and one Interregional Clinical Research Organization.
This is the DNA of the cluster to feed local excellence, including, of course, fundamental and applied immunology, and to support the emergence of sector initiatives with strong potential. Marseille Immunopole is a perfect illustration of this approach and we are very proud of the magnitude taken today by this new operation initiated in 2013. Eurobiomed still remains very involved, animating the community and participating in the driving force that allows the creation of start-ups and the development of industrials and service companies in MI and the implementation of ambitious partnerships in France and internationally on these issues.#ecosystème
New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.
Immunotherapy is expanding to other cancers types: kidney cancer, bladder cancer, hepatocellular carcinoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma… but we are still only at the beginning of the story!
Each year, a large number of clinical trials are conducted by APHM clinicians alone or in partnership with industry players in biopharmaceuticals.
AMU, AP-HM, CIML
MI today is a great accomplishment as it brings together for the first time all the expertise in immunology but it is above a new strategic step for all Marseille immunology players